Researchers decided to look at the relationship between having mesothelioma in addition to a second cancer and their impact on survival. Researchers found that a second cancer did not affect survival for most patients with mesothelioma, but for patients with a specific type of mesothelioma, survival was affected. Mesothelioma is[…]
Mesothelioma
Cytoreductive Surgery and Chemotherapy Improved for Mesothelioma
Improvements have been made for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). This treatment combination is typically performed on people with cancers in the abdominal region. One such cancer is peritoneal mesothelioma. Peritoneal mesothelioma is a cancer of the lining of the abdomen caused by asbestos exposure. Peritoneal mesothelioma is[…]
Keytruda Helps Improve Survival for Mesothelioma When Used Alongside Chemotherapy
Keytruda is showing promising results for the treatment of pleural mesothelioma. Researchers found that the combination of Keytruda (pembrolizumab) and chemotherapy lead to a better survival in patients versus chemotherapy alone. Mesothelioma is a hard-to-treat cancer with no cure. It can be found in the linings of the lungs, abdomen,[…]
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma (Immuno-MESODEC)
Primary Outcome Measures Proportion of patients that experienced (S)AEs possibly, probably or definitely related to pemetrexed and/or cisplatin/carboplatin and/or atezolizumab and/or WT1/DC vaccination [ Time Frame: through study completion, an average of 2 years ] The relationship of an AE to the investigational agents will be determined by the Investigator as either related or[…]
BAP1 and Mesothelioma Risk
Researchers have found at least one way that asbestos causes mesothelioma. The disease is linked to the HMGB1 protein. Researchers looked at a mesothelioma epidemic in Türkiye, noting that in some families, up to 50 percent develop mesothelioma. Family members passed the likelihood of mesothelioma from generation to generation. Families[…]
A Vaccine to Prevent and Treat Mesothelioma Could be Possible in the Future
A vaccine for lung cancer could possibly lead to a vaccine for mesothelioma. The lung cancer immunotherapy drug CIMAvax-EFG is making great progress, and because of this progress, researchers are utilizing the treatment in new ways. The researchers are trying to see how the vaccine can be used to prevent[…]
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Primary Outcome Measures Phase 1 Maximum Tolerated Dose [ Time Frame: 28 days ] To determine the maximum tolerated dose (MTD) of TNG462 Phase 1 Dosing Schedule [ Time Frame: 28 days ] To determine the dosing schedule of TNG462 Phase 2 Anti-neoplastic Activity [ Time Frame: 16 weeks ] To assess anti-neoplastic activity of TNG462 in patients with MTAP-deleted advanced solid[…]
Gene Suppressor Therapy Could Improve Survival for Mesothelioma Patients
New mesothelioma research is being performed at The Netherlands Cancer Institute. The researchers are looking at new combinations of medications to be used on patients that have mesothelioma with BAP1 genetic mutations. More than half of patients with mesothelioma have changes in the BAP1 tumor suppressor gene. When the BAP1[…]
Using MicroRNA as a Biomarker to Diagnose Mesothelioma
The early diagnosis and treatment of mesothelioma is critical for extending survival in patients. Researchers in Italy may have found a helpful biomarker to catch mesothelioma earlier, up to five years before a clinical diagnosis. This is helpful because once mesothelioma is diagnosed, it is hard to treat due to[…]
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Primary Outcome Measures Number of patients tolerating dose levels (maximum tolerated dose; MTD) in each of the combinations [ Time Frame: Assessed from baseline to 30 days after last dose of study drug ] MTD of NUC-3373 in each of the combinations in each patient Number of patients reporting treatment-emergent adverse events (TEAEs) in[…]
